U.S. Heparin Market Size & Share 2020 to 2026

U.S. Heparin Market Size

U.S. Heparin Market size exceeded USD 623 million in 2019 and is poised to grow at over 7.2% CAGR between 2020 and 2026. Increasing patient pool suffering from chronic illness and rising demand for anticoagulant products will drive the market growth.

Heparin is primarily used in blood transfusion, deep vein thrombosis and kidney dialysis, among others. For instance, according to the National Kidney Foundation report, more than 37 million (15%) individual of U.S. adults are affected by chronic kidney disease (CKD). The report also stated that CKD causes more deaths than breast cancer or prostate cancer. It is one of the under-recognized public health crises. This indicates that there will huge number of patient pool suffering from such disease. Such high prevalence of the disease will increase the heparin market demand in the U.S.
 

Heparin is an essential anticoagulant drug that are used in critical life-saving surgical procedures. Thus, it can be expected that the COVID-19 outbreak will not directly impact on the manufacturing of products. However, there can be logistical disruptions especially due to the high reliance on Chinese manufacturing. This could disrupt the supply system of heparin and may cause temporary shortages. This can potentially increase the price of heparin API.
 

U.S. Heparin Market Trends

The demand for anti-coagulant drugs is on the rise across the U.S. on account of the dependence of most of the vital surgeries on heparin for appropriate and desired outcomes. For instance, procedures such as open-heart surgery, hemodialysis, and interventional procedures are mainly dependent on heparin. Similarly, according to the American Heart Association (AHA) report, coronary heart disease causes around 1 in 7 deaths in U.S aged 25 years and above. The report also stated that, about 3% of the total American suffer from myocardial infarction. This has led to increase in demand for heparin treatment. Such rising cases of chronic illness in both middle aged as well as geriatric people will augment the industry growth.
 

High dependency on porcine-sourced heparin may hamper the market growth

High dependency on porcine-sourced heparin will restrict the U.S. heparin market size expansion. In U.S., the bovine-sourced heparin was withdrawn due to the spread of bovine spongiform encephalopathy disease in cattle, hence porcine-sourced heparin is the only heparin used in the U.S. Furthermore, the outbreak of swine fever in 2017 has affected about one third of the pig’s population, thus hampering the heparin API supply. However, FDA has encouraged to re-introduce bovine-sourced heparin in U.S. to lower the dependency on porcine that may have positive impact on the market demand.
 

U.S. Heparin Market Analysis

The low molecular weight heparin market valuation in the U.S. was more than USD 535.4 million in 2019. Low molecular weight heparin are heterogenous compounds and have distinct biochemical and pharmacological properties. Low molecular weight heparin produces a more predictable anticoagulant response, has longer shelf-life and does not require frequent monitoring. Such properties and various applications associated with low molecular weight heparin will increase the adoption rate. Additionally, increasing demand in various healthcare settings owing to growing burden of cardiovascular and chronic diseases will boost the market revenue.   
 

The venous thromboembolism segment size was over USD 328 million in 2019 and is expected to show lucrative growth of 6.8% during the forecast period. Growing rate of chronic diseases including venous thromboembolism will serve as a major factor responsible for the U.S. heparin market growth. For instance, as per the Centers for Disease Control & Prevention (CDC) estimates, about 900,000 people are affected annually by thromboembolism in the U.S. This implicates that there will be a constant increase in the number of patients requiring heparin for treatment of venous thromboembolism. Such high number of chronic conditions will lead to an increased demand for heparin injections for treatment.
 

Hospital pharmacy segment in the U.S. accounted for 54.3% heparin market share in 2019. Patients tend to prefer hospitals more as compared to other healthcare settings as they offer high quality care and ease of availability of medicines. Hospital pharmacies mainly stock and monitor the supply of larger range of medications that are used in the hospital. Furthermore, constant availability and supply of specialized and life-saving medications will supplement the segment growth.
 

U.S. Heparin Market Share

Notable players operating in the U.S. heparin market include:

• Pfizer
• Amphastar Pharmaceutical
• Sanofi
• Shenzhen Hepalink
• Fresenius Kabi
• Nanjing King-Friend Biochemical Pharmaceutical.

Product launches & approvals, partnerships and geographical expansions are the most adopted business strategies to sustain market competition.
 

Some of the recent industry developments:

• In May 2020, Nanjing King-Friend Biochemical and Meitheal Pharmaceuticals, Inc., a fully integrated generic injectables company announced the launch of Enoxaparin Sodium Injection, USP, the generic equivalent of Lovenox, in the U.S. market. This is expected to enhance the Nanjing King-Friend Biochemical’s customer base and strengthen its market presence in the U.S.
   
• In November 2019, Fresenius Kabi launched its new and simplest prefilled syringe of 5,000 USP units per 0.5 ml of Heparin sodium injection in U.S. market. The product is ready to administer in prefilled syringe. This strategy has expanded the company’s product portfolio and customer base as well as geographic outreach.
   

The U.S. heparin market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Low molecular weight heparin
• Unfractionated heparin

Market, By Application

• Venous thromboembolism
• Atrial fibrillation/flutter
• Coronary artery disease
• Others

Market, By Distribution Channel

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy